Methadone and Buprenorphine for the Management of Opioid Dependence in Pregnancy

This article provides an overview and discussion of the collective maternal, fetal and neonatal outcome research on women maintained on methadone or buprenorphine during pregnancy. Its focus is on an assessment of the comparative effectiveness of methadone and buprenorphine pharmacotherapy, with particular attention given to recent findings from the literature. Recommendations for clinical practice are outlined, and directions for future research are presented.Findings from comparative studies of methadone and buprenorphine underscore the efficacy of both medications in preventing relapse to illicit opioid use in the treatment of opioid-dependent pregnant patients, as well as the simplicity of induction onto methadone and patient retention while receiving such therapy. Fetal monitoring suggests that buprenorphine results in less fetal cardiac and movement suppression than does methadone. The clinical implications of these findings need future exploration. For the neonate, evidence from studies using a wide range of designs, including retrospective chart reviews, prospective observational studies, and randomized clinical trials, show consistent results, with prenatal exposure to buprenorphine resulting in less severe neonatal abstinence syndrome relative to methadone.Any medication given to pregnant women should be prescribed only after considering the risk: benefit ratio for the maternal-fetal dyad. Medication choices for each opioid-dependent patient during pregnancy need to be made on a patient-by-patient basis, taking into consideration the patient’s opioid dependence history, previous and current treatment experiences, medical circumstances and treatment preferences. Moreover, for a full remission of opioid addiction to be sustainable, both post-partum and across the lifespan, treatment providers must not rely solely on medication to treat their patients but should also utilize women-specific comprehensive treatment models that address the underlying multifaceted complexities of their patient’s lives.

[1]  J. DiPietro,et al.  Fetal response to maternal methadone administration. , 2005, American journal of obstetrics and gynecology.

[2]  J. Chennat,et al.  Maternal methadone dose and neonatal withdrawal. , 2003, American journal of obstetrics and gynecology.

[3]  H. Jones,et al.  Neonatal abstinence syndrome. , 2012, JAMA.

[4]  A. Eschenroeder,et al.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ‐opioid‐ and nociceptin/orphanin FQ receptors in cell development: Implications for drug addiction treatment during pregnancy , 2012, Glia.

[5]  B. Stimmel,et al.  Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used. , 1982, The American journal of drug and alcohol abuse.

[6]  G. Badger,et al.  Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. , 2012, Addiction.

[7]  L. Finnegan Perinatal substance abuse: comments and perspectives. , 1991, Seminars in perinatology.

[8]  L. Finnegan,et al.  Opioid dependence during pregnancy. Effects and management. , 1998, Obstetrics and gynecology clinics of North America.

[9]  W. H. Hall,et al.  Effective medical treatment of opiate addiction , 1998 .

[10]  R. Newman ["Is opiate detoxification unsafe in pregnancy?"]. , 2004, Journal of substance abuse treatment.

[11]  T. Fahey,et al.  Methadone and perinatal outcomes: a retrospective cohort study. , 2011, American journal of obstetrics and gynecology.

[12]  W. Leblanc,et al.  Methadone withdrawal in newborn infants. , 1972, The Journal of pediatrics.

[13]  Amy L. Salisbury,et al.  Neonatal neurobehavior effects following buprenorphine versus methadone exposure. , 2012, Addiction.

[14]  R. Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2003, The Cochrane database of systematic reviews.

[15]  H. Jones,et al.  The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. , 2001, Drug and alcohol dependence.

[16]  G. Hankins,et al.  The effect of methadone and buprenorphine on human placental aromatase. , 2006, Biochemical pharmacology.

[17]  K. Thau,et al.  Association between Prenatal Tobacco Exposure and Outcome of Neonates Born to Opioid-Maintained Mothers , 2009, European Addiction Research.

[18]  N. Haug,et al.  Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women. , 1997, Drug and alcohol dependence.

[19]  L. Finnegan,et al.  Treatment issues for opioid-dependent women during the perinatal period. , 1991, Journal of psychoactive drugs.

[20]  Amber M. Holbrook,et al.  Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. , 2012, Addiction.

[21]  L. Finnegan,et al.  Perinatal and developmental outcome of infants exposed to methadone in-utero. , 1987, NIDA research monograph.

[22]  J. Lowinson Substance Abuse: A Comprehensive Textbook , 1992 .

[23]  M. Curley,et al.  The Withdrawal Assessment Tool–1 (WAT–1): An assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients* , 2008, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[24]  Brandy Drake Maternal Treatment with Opioid Analgesics and Risk for Birth Defects , 2011 .

[25]  G. Hankins,et al.  Transfer of methadone across the dually perfused preterm human placental lobule. , 2008, American journal of obstetrics and gynecology.

[26]  G. Hulse,et al.  Naltrexone implant and blood naltrexone levels over pregnancy , 2003, The Australian & New Zealand journal of obstetrics & gynaecology.

[27]  L. Platt,et al.  Antepartum fetal evaluation: development of a fetal biophysical profile. , 1980, American journal of obstetrics and gynecology.

[28]  J. Dashe,et al.  Relationship Between Maternal Methadone Dosage and Neonatal Withdrawal , 2002, Obstetrics and gynecology.

[29]  H. Jones,et al.  Maternal treatment with opioid analgesics and risk for birth defects: additional considerations. , 2011, American journal of obstetrics and gynecology.

[30]  B. Lask,et al.  Implications for Treatment , 2011 .

[31]  A. Eidelman,et al.  The narcotic-dependent mother: fetal and neonatal consequences. , 1977, Early human development.

[32]  L. Finnegan,et al.  Neonatal abstinence syndrome: assessment and management. , 1975, Addictive diseases.

[33]  E. Sanchez,et al.  Opioid addiction and pregnancy: Perinatal exposure to buprenorphine affects myelination in the developing brain , 2008, Glia.

[34]  H. Aschauer,et al.  Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. , 2006, Addiction.

[35]  G. Hulse,et al.  Using naltrexone implants in the management of the pregnant heroin user , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.

[36]  W. Rayburn,et al.  Effect of Chronic Maternal Methadone Therapy on Intrapartum Fetal Heart Rate Patterns , 2006, The Journal of the Society for Gynecologic Investigation: JSGI.

[37]  L. Finnegan Introduction to Women, Children and Addiction , 2010, Journal of addictive diseases.

[38]  L. Finnegan,et al.  Assessment and treatment of abstinence in the infant of the drug-dependent mother. , 1975, International journal of clinical pharmacology and biopharmacy.

[39]  N. Benowitz,et al.  Altered methadone pharmacokinetics in methadone-maintained pregnant women. , 1985, The Journal of pharmacology and experimental therapeutics.

[40]  H. Jones,et al.  Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. , 2008, The American journal on addictions.

[41]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[42]  B. Lester,et al.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. , 2005, Drug and alcohol dependence.

[43]  R. Hoekelman Primary Pediatric Care , 1987 .

[44]  G. Hulse,et al.  Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user , 2004, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[45]  P. Janssen,et al.  Rooming-in compared with standard care for newborns of mothers using methadone or heroin. , 2007, Canadian family physician Medecin de famille canadien.

[46]  S. Blatman Methadone effects on pregnancy and the newborn. , 1973, Proceedings. National Conference on Methadone Treatment.

[47]  A. Flynn,et al.  A randomized controlled trial of non‐stress antepartum cardiotocography , 1982, British journal of obstetrics and gynaecology.

[48]  C. Sinha,et al.  The effect of maternal methadone use on the fetal heart pattern: a computerised CTG analysis , 2006, BJOG : an international journal of obstetrics and gynaecology.

[49]  G. Merenstein,et al.  Handbook of neonatal intensive care , 1990 .

[50]  G. Blinick Menstrual Function and Pregnancy in Narcotics Addicts treated with Methadone , 1968, Nature.

[51]  C. Brewer,et al.  Obstetric and neonatal outcomes associated with maternal naltrexone exposure , 2001, The Australian & New Zealand journal of obstetrics & gynaecology.

[52]  E. Lyons,et al.  A scoring system for nonstressed antepartum fetal heart rate monitoring. , 1979, American journal of obstetrics and gynecology.

[53]  P. Friedmann,et al.  Relationships Between Maternal Methadone Dosage, Maternal-Neonatal Methadone Levels, and Neonatal Withdrawal , 1993, Obstetrics and gynecology.

[54]  Karol Kaltenbach Exposure to opiates: behavioral outcomes in preschool and school-age children. , 1996, NIDA research monograph.

[55]  R. Newman,et al.  Results of 313 consecutive live births of infants delivered to patients in the New York City Methadone Maintenance Treatment Program. , 1975, American journal of obstetrics and gynecology.

[56]  I. Wilets,et al.  Neonatal opiate abstinence syndrome in term and preterm infants. , 1991, The Journal of pediatrics.

[57]  H. Evans,et al.  Narcotic withdrawal in the newborn. , 1972, American family physician.

[58]  J. Ager,et al.  Effects of case management on retention in prenatal substance abuse treatment. , 1996, The American journal of drug and alcohol abuse.

[59]  A. Acar,et al.  Comparison of Modified Biophysical Profile and Doppler Ultrasound in Predicting the Perinatal Outcome at or over 36 Weeks of Gestation , 2010, Gynecologic and Obstetric Investigation.

[60]  P. Lipsitz A Proposed Narcotic Withdrawal Score for Use with Newborn Infants , 1975, Clinical pediatrics.

[61]  R. Wallach,et al.  Drug addiction in pregnancy and the neonate. , 1976, American journal of obstetrics and gynecology.

[62]  Z. Hodgson,et al.  An evaluation of rooming-in among substance-exposed newborns in British Columbia. , 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[63]  L. Kuessel,et al.  First-trimester fetal heart rate in mothers with opioid addiction. , 2010, Addiction.

[64]  Amber M. Holbrook,et al.  Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. , 2012, Addiction.

[65]  L. Simmat-Durand,et al.  Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. , 2006, Drug and alcohol dependence.

[66]  M. Stitzer,et al.  Methadone treatment for opioid dependence , 1999 .

[67]  P. Marquet,et al.  Case Study of Neonates Born to Mothers Undergoing Buprenorphine Maintenance Treatment , 2002 .

[68]  H. Jones,et al.  Fetal neurobehavioral effects of exposure to methadone or buprenorphine. , 2011, Neurotoxicology and teratology.

[69]  L. Finnegan,et al.  Perinatal addiction: outcome and management. , 1977, American journal of obstetrics and gynecology.

[70]  Substance Abuse in Women: Does Gender Matter? , 2007 .

[71]  G. Hulse,et al.  A possible role for implantable naltrexone in the management of the high‐risk pregnant heroin user , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.

[72]  K. Nicolaides,et al.  Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. , 1993, American journal of obstetrics and gynecology.

[73]  T. Gunn,et al.  The effect of methadone treatment on the quantity and quality of human fetal movement. , 2004, Neurotoxicology and teratology.

[74]  C. Lenstrup,et al.  PREDICTIVE VALUE OF ANTEPARTUM FETAL HEART RATE NON‐STRESS TEST IN HIGH‐RISK PREGNANCY , 1985, Acta obstetricia et gynecologica Scandinavica.

[75]  P. Marquet,et al.  Buprenorphine therapy of opiate addiction. , 2002 .

[76]  Amy L. Salisbury,et al.  Fetal assessment before and after dosing with buprenorphine or methadone. , 2012, Addiction.